CH395999A - Process for the preparation of α-pyrrolidino-valerophenones - Google Patents

Process for the preparation of α-pyrrolidino-valerophenones

Info

Publication number
CH395999A
CH395999A CH286565A CH286565A CH395999A CH 395999 A CH395999 A CH 395999A CH 286565 A CH286565 A CH 286565A CH 286565 A CH286565 A CH 286565A CH 395999 A CH395999 A CH 395999A
Authority
CH
Switzerland
Prior art keywords
pyrrolidino
preparation
formula
acid
valerophenones
Prior art date
Application number
CH286565A
Other languages
German (de)
Inventor
Wilhelm Dr Heffe
Original Assignee
Wander Ag Dr A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wander Ag Dr A filed Critical Wander Ag Dr A
Priority to CH286565A priority Critical patent/CH395999A/en
Publication of CH395999A publication Critical patent/CH395999A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  
 



  Verfahren zur Herstellung von   a-Pyrrolidirlo-valerophenollell   
Gegenstand der Erfindung ist ein Verfahren zur Herstellung von neuen   a-Pyrrolidin o-valerophenonen    der Formel:
EMI1.1     
 worin R Wasserstoff, ein Chloratom, eine Methyloder eine Methoxygruppe bedeutet, oder von Säure  Additionssalzen    dieser Basen.



   Substanzen der obigen Formel bzw. ihre Salze, z. B. die Hydrohalogenide, besitzen gute zentral erregende Wirkung ohne   unerwünschteNebenwirkungenl,    wie Kreislaufwirkungen.



   Diese Wirkung ist für die erfindungsgemäss her  stellbare    Verbindungen sehr spezifisch. Geringfügige Abweichungen von der angegebenen Formel   (1)      üh-    ren, wie sich gezeigt hat, zu einer Herabsetzung oder zum Verlust der zentral   stimullerenden    Wirkung oder zum Auftreten unerwünschter Nebenwirkungen. Zum Beispiel geht die zentral erregende Wirkung in folgenden Fällen teilweise oder ganz   verloren:    wenn ein Substituent R in einer anderen Stellung als der p Stellung ist oder, wenn er im Benzolkern mehrfach auftritt (z.

   B. 3,4-Di-R- oder   3,4,5-Tri-R-Verbindun-      gen);    wenn im Substituenten R Alkyl- oder Alkoxy   gruppen mit mehr als s einem C-Atom auftreten; ; wenn    die Oxogruppe zur Hydroxygruppe reduziert wird; wenn das Wasserstoffatom am tertiären C-Atom durch eine Alkylgruppe zersetzt wird; oder wenn die   Propyigruppe    am tertiären C-Atom durch eine Alkylgruppe mit weniger als 3   C-Atomen    ersetzt wird.



   Die beschriebenen neuen a-Pyrrolidino-valerophenone (I) werden erfindungsgemäss erhalten, indem man ein gegebenenfalls am Stickstoff   mono-    oder disubstituiertes Carbonsäureamid der Formel :
EMI1.2     
 unter wasserfreien Bedingungen mit einem   piR-    Phenyl-magnesiumhalogenid umsetzt und die gebil   dete    organometallische Verbindung hydrolysiert. Die Umsetzung kann z. B. in wasserfreiem   Äther    oder Tetrahydrofuran bei Zimmertemperatur oder erhöh  ter    Temperatur vorgenommen werden.



   Die   Säure-Additionssalze    der Basen entsprechend Formel (I) kann man in üblicherWeise   durch      Uniset-    zen der Basen mit geeigneten anorganischen oder organischen Säuren, wie
Chlorwasserstoffsäure, Bromwasserstoffsäure,
Schwefelsäure, Phosphorsäure, Essigsäure,
Weinsäure, Maleinsäure, Oxalsäure,
Citronensäure und dergleichen, erhalten.



   Die erfindungsgemäss erhältlichen Produkte mit zentral stimulierender Wirkung können unter Verwendung der üblichen Träger-,   Hilfs- und    Füllstoffe in passenden Applikationsformen verabreicht werden, z. B. in Form von   Tabletten    oder Dragees mit etwa 5 bis 60 mg Wirkstoff oder von Suppositorien mit etwa 10 bis 60 mg Wirkstoff.



   Beispiel
Eine Grignard-Lösung, hergestellt aus 17 g Brombenzol in 100 ml absolutem   Ather    und 2,5 g Magnet siumspänen, wird unter Rühren und Kühlen langsam mit einer Lösung von 14 g   a-Pyrrolidino-n-valerian-    säureamid in 150 ml absolutem Dioxan versetzt. Die Mischung wird unter Rühren während 10   StuPdsPa     auf Rückfluss erhitzt. Man zersetzt das   Reaktionsu    produkt mit Eis und verdünnter Salzsäure, schüttelt die organische Phase zweimal mit verdünnter Salzsäure aus, macht die vereinigten salzsauren Auszüge mit verdünnter Natronlauge alkalisch und schüttelt mit Benzol aus. Die benzolische Lösung wird dreimal mit Wasser gewaschen, über Natriumsulfat getrocknet, mit 2n Salzsäure angesäuert und im Vakuum zur Trockne eingedampft.

   Beim Umkristallisieren aus Aceton erhält man 17 g a-Pyrrolidino-n-valerophenon-monohydrat-Hydrochlorid, Smp.   1041060    C.    a - Pyrrolidino -n-valerophenon-Hydrochlorid    und sein Hydrat sind fast unlöslich in Aceton, leicht löslich in Wasser, Methanol und Alkohol. Sie lassen sich sehr gut umkristallisieren aus der   Sfachen    Menge Aceton unter Zusatz von etwa 1 Mol   H2O.    Man erhält direkt   91-94 %    des Rohproduktes an reiner Substanz und nach Aufarbeitung der Mutterlauge 98 %.



  Die so erhaltene Substanz hat den Schmelzpunkt 104 bis   1060 C,    welcher sich nach Austreiben von 6% H2O auf   169-1700    C (wasserfreie Form) erhöht.



   Bei gleichem Vorgehen wie im vorerwähnten Beispiel erhält man aus entsprechenden Ausgangsmaterialien ferner z. B. a-Pyrrolidino-p-methoxy-n-valerophenon
Hydrochlorid, Smp. 1770 C,    a-Pyrrolidino-p-methyl-n-valerophenon-   
Hydrochlorid, Smp. 1780 C, sowie    a-Pyrrolidino-p-chlor-n-valeroph, enon-   
Hydrochlorid, Smp.   203-2080    C.   



  
 



  Process for the preparation of α-pyrrolidirlovalerophenollell
The invention relates to a process for the preparation of new a-pyrrolidine o-valerophenones of the formula:
EMI1.1
 where R is hydrogen, a chlorine atom, a methyl or a methoxy group, or acid addition salts of these bases.



   Substances of the above formula or their salts, e.g. The hydrohalides, for example, have good central excitatory effects without undesirable side effects such as circulatory effects.



   This effect is very specific for the compounds which can be produced according to the invention. As has been shown, slight deviations from the specified formula (1) lead to a reduction or loss of the central stimulating effect or to the occurrence of undesirable side effects. For example, the central excitatory effect is partially or completely lost in the following cases: if a substituent R is in a position other than the p position or if it occurs several times in the benzene nucleus (e.g.

   B. 3,4-Di-R or 3,4,5-Tri-R compounds); if alkyl or alkoxy groups with more than one carbon atom occur in the substituent R; ; when the oxo group is reduced to the hydroxy group; when the hydrogen atom on the tertiary carbon atom is decomposed by an alkyl group; or if the propylene group on the tertiary carbon atom is replaced by an alkyl group with fewer than 3 carbon atoms.



   The novel a-pyrrolidino-valerophenones (I) described are obtained according to the invention by adding a carboxamide of the formula, optionally mono- or disubstituted on the nitrogen:
EMI1.2
 reacted under anhydrous conditions with a piR-phenyl-magnesium halide and hydrolyzed the formed organometallic compound. The implementation can e.g. B. be made in anhydrous ether or tetrahydrofuran at room temperature or elevated temperature.



   The acid addition salts of the bases corresponding to formula (I) can be prepared in a customary manner by uniset- zen the bases with suitable inorganic or organic acids, such as
Hydrochloric acid, hydrobromic acid,
Sulfuric acid, phosphoric acid, acetic acid,
Tartaric acid, maleic acid, oxalic acid,
Citric acid and the like.



   The products with a centrally stimulating effect obtainable according to the invention can be administered in suitable application forms using the customary carriers, auxiliaries and fillers, e.g. B. in the form of tablets or dragees with about 5 to 60 mg of active ingredient or of suppositories with about 10 to 60 mg of active ingredient.



   example
A Grignard solution, prepared from 17 g of bromobenzene in 100 ml of absolute ether and 2.5 g of magnetic siumspänen, is slowly mixed with a solution of 14 g of a-pyrrolidino-n-valeric acid amide in 150 ml of absolute dioxane while stirring and cooling . The mixture is heated to reflux for 10 hours while stirring. The reaction product is decomposed with ice and dilute hydrochloric acid, the organic phase is extracted twice with dilute hydrochloric acid, the combined hydrochloric acid extracts are made alkaline with dilute sodium hydroxide solution and extracted with benzene. The benzene solution is washed three times with water, dried over sodium sulfate, acidified with 2N hydrochloric acid and evaporated to dryness in vacuo.

   Recrystallization from acetone gives 17 g of a-pyrrolidino-n-valerophenone monohydrate hydrochloride, m.p. 1041060 C. a - Pyrrolidino-n-valerophenone hydrochloride and its hydrate are almost insoluble in acetone, easily soluble in water, methanol and Alcohol. They can be recrystallized very well from six times the amount of acetone with the addition of about 1 mol of H2O. 91-94% of the pure substance of the crude product is obtained directly, and 98% after working up the mother liquor.



  The substance thus obtained has a melting point of 104 to 1060 C, which increases to 169-1700 C (anhydrous form) after 6% H2O has been expelled.



   Using the same procedure as in the aforementioned example, appropriate starting materials also give z. B. a-pyrrolidino-p-methoxy-n-valerophenone
Hydrochloride, m.p. 1770 C, a-pyrrolidino-p-methyl-n-valerophenone
Hydrochloride, m.p. 1780 C, and a-pyrrolidino-p-chloro-n-valeroph, enone
Hydrochloride, m.p. 203-2080 C.

 

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung von a-Pyrrolidinovalerophenonen der Formel: EMI2.1 worin R Wasserstoff, ein Chloratom, eine Methyloder eine Methoxygruppe bedeutet, oder von Salzen dieser Basen, dadurch gekennzeichnet, dass man ein gegebenenfalls am Stickstoff mono-oder oder disubstitu- inertes Carbonsäureamid der Formel: EMI2.2 unter wasserfreien Bedingungen mit einem p-R-Phe nyimagnesium-halogenid umsetzt, die gebildete or gunometalliscae Verbindung hydrolysiert und das Produkt als freie Base oder in Form eines Säure- Additionssalzes gewinnt. PATENT CLAIM Process for the preparation of a-pyrrolidinovalerophenones of the formula: EMI2.1 in which R denotes hydrogen, a chlorine atom, a methyl or a methoxy group, or of salts of these bases, characterized in that a carboxamide of the formula which is optionally mono- or disubstituted on nitrogen is used: EMI2.2 reacts under anhydrous conditions with a p-R-Phe nyimagnesium halide, hydrolyzes the formed or gunometalliscae compound and wins the product as a free base or in the form of an acid addition salt.
CH286565A 1961-05-05 1961-05-05 Process for the preparation of α-pyrrolidino-valerophenones CH395999A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH286565A CH395999A (en) 1961-05-05 1961-05-05 Process for the preparation of α-pyrrolidino-valerophenones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH286565A CH395999A (en) 1961-05-05 1961-05-05 Process for the preparation of α-pyrrolidino-valerophenones

Publications (1)

Publication Number Publication Date
CH395999A true CH395999A (en) 1965-07-31

Family

ID=4243319

Family Applications (1)

Application Number Title Priority Date Filing Date
CH286565A CH395999A (en) 1961-05-05 1961-05-05 Process for the preparation of α-pyrrolidino-valerophenones

Country Status (1)

Country Link
CH (1) CH395999A (en)

Similar Documents

Publication Publication Date Title
AT226694B (en) Process for the preparation of new α-pyrrolidino-valerophenones
CH395999A (en) Process for the preparation of α-pyrrolidino-valerophenones
CH438352A (en) Process for the preparation of diphenylalkylamines
CH395998A (en) Process for the preparation of α-pyrrolidino-valerophenones
DE959460C (en) Process for the production of lactams
AT226692B (en) Process for the preparation of new α-pyrrolidino-valerophenones
AT226693B (en) Process for the preparation of new α-pyrrolidino-valerophenones
AT215424B (en) Process for the production of xanthenes or thiaxanthenes
DE1470264C3 (en) Process for the preparation of 1-phenyl-1 - square brackets on thienyl- (2) square brackets to -carbinols
DE1518020C (en) 4 (4 chlorophenoxy) 3 hydroxy 4 methylvaleric acid, their lower alkyl esters and physiologically acceptable salts, processes for their manufacture and drugs containing these compounds
AT203495B (en) Process for the preparation of new tertiary amines
DE897406C (en) Process for the preparation of pyrazolone compounds
DE1620536C (en) Process for the production of alpha pyrrolidinoketones and their salts
AT218017B (en) Process for the preparation of ketones of 4-hydroxy-coumarin
AT217026B (en) Process for the preparation of new α-aminoisobutyrophenone compounds and their acid addition salts
AT219036B (en) Process for the preparation of new 3-substituted 1-benzylindanes and their salts
AT227256B (en) Process for the production of new aminoindanes and their salts
DE1445184C (en) Process for the preparation of alpha-pyrrolidino-n-valerophenones and their salts
AT205962B (en) Process for the preparation of new unsaturated aliphatic amino diols
AT206899B (en) Process for the preparation of new, substituted 3,5-dioxo-tetrahydro-1,2,6-thiadiazine-1,1-dioxyden
DE963513C (en) Process for the preparation of therapeutically valuable condensation products from Diels-Alder addition compounds of dienes to quinones
DE959097C (en) Process for the preparation of basic substituted diarylacetonitriles
AT244327B (en) Process for the preparation of diphenylalkylamines and their physiologically acceptable salts
AT234687B (en) Process for the production of new benzodioxane derivatives and their acid addition salts
DE1620710A1 (en) Process for the production of compounds with a central excitatory effect